Company: CDT
Filing Date: 2025-06-03
Form Type: 8-K
Source: 0001641172-25-013468
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-06-03
Form: 8-K
Item: Item 5.08
Chunk 0
---
Item
5.08 Shareholder Director Nominations.

The
Board of Directors (the “ Board”) of Conduit Pharmaceuticals Inc. (the “ Company”) has established August 5, 2025
as the date for its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The Board also established July 3, 2025,
as the record date for the 2025 Annual Meeting.

Since
the date of the 2025 Annual Meeting is more than 30 days before the anniversary of the date of the Company’s 2024 Annual Meeting
of Stockholders, the Company is filing this Current Report on Form 8-K to inform stockholders of this change and to provide the due date
for the submission of any qualified stockholder proposals or qualified stockholder director nominations.

Stockholders
of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting
pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 (the “ Exchange Act”), must ensure that such proposal is
received by the Company’s Secretary at its principal executive offices on or before the close of business on June 17, 2025, which
the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials in accordance with
Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act. Any such proposal must also meet the requirements set forth in the rules and
regulations of the Securities and Exchange Commission in order to be eligible for inclusion in the proxy materials for the 2025 Annual
Meeting.

In
addition, in accordance with the requirements contained in the Company’s bylaws, stockholders of the Company who wish to bring
business before the 2025 Annual Meeting outside of Rule 14a-8 of the Exchange Act or to nominate a person for election as a director
must ensure that written notice of such proposal (including all information specified in the Company’s bylaws) is received by the
Company’s Secretary at the Company’s principal executive offices no later than the close of business on June 17, 2025. Any
such proposal must meet the requirements set forth in the Company’s bylaws to be brought before the 2025 Annual Meeting.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this